Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress
the immune system (called immunosuppressive regimens) to stop the immune system from
attacking the transplanted kidney in order to limit damage to or the possibility of rejecting
the transplanted kidney. The purpose of this study is to evaluate benefits and risks of two
immunosuppressive regimens (belatacept with everolimus or tacrolimus with mycophenolate
mofetil) following thymoglobulin induction and rapid corticosteroid withdrawal.